Eva Walde

Board member | Life Science | Commercial Scaling | International Expansion | Angel Investor

📍 Sweden🔄 Updated September 2026💼 7 investments📅 8 years investing🗓 Last invested Apr 2026
VC🌍 SwedenInvested this year
7
Total investments
0
Early stage
1
Mid stage
0
Late stage
8y
Years active

Portfolio

4 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
Apr 2026
Angel investor network formed by seasoned entrepreneurs investing smart money in life science.
Board Member
2024
Angel investor network formed by seasoned entrepreneurs investing smart money.
Board Member
Nov 2023
Epigenica is a life sciences technology company at the forefront of innovations in epigenetic research. The company’s EpiFinder platform enables researchers to perform comprehensive epigenetic studies at unprecedented speed, scalability, and affordability. Epigenica is building a portfolio of products based on the EpiFinder platform to offer comprehensive high-throughput profiling at different depths of detail with an array of possible starting materials. The platform is powered by the company’s patented and proprietary high-throughput, multiplex, quantitative ChIP-seq technology (hmqChIP), the first commercial kit of its kind. With the advantages of the EpiFinder platform, Epigenica is helping researchers advance biomedical research, drug discovery and development, precision medicine, diagnostics, and therapeutics for aging and longevity.
mid stageBiotechnology
Board Member, Co-owner and Investor
Feb 2023
Angel investor network formed by seasoned entrepreneurs investing smart money.
Experience · 7 entries
All (7)
Investments (6)
Founder (1)
Board (6)
2026
Board Member
Apr 2026
Angel investor network formed by seasoned entrepreneurs investing smart money in life science.
2024
Board Member
2024
Angel investor network formed by seasoned entrepreneurs investing smart money.
2023
Board Member
Nov 2023
FrostPharma is an entrepreneurial Swedish Specialty Pharma company specializing in the commercialization of value-adding medicines. FrostPharma signed its first product distribution agreement in 2017, and since then 35 products have been added to the therapy agnostic portfolio through a strong agreement deal-flow, as well as through the development of proprietary products. The company has an established specialty pharma platform across the Nordics, and now actively plan to expand to additional EU countries. The FrostPharma portfolio of products are primarily oriented toward hospital use, and hospital initiation. FrostPharma has also developed a separate division offering sustainable solutions to petroleum based plastics across the Healthcare sector. Please contact us at: info@frostpharma.com
Board Member
Nov 2023
Epigenica is a life sciences technology company at the forefront of innovations in epigenetic research. The company’s EpiFinder platform enables researchers to perform comprehensive epigenetic studies at unprecedented speed, scalability, and affordability. Epigenica is building a portfolio of products based on the EpiFinder platform to offer comprehensive high-throughput profiling at different depths of detail with an array of possible starting materials. The platform is powered by the company’s patented and proprietary high-throughput, multiplex, quantitative ChIP-seq technology (hmqChIP), the first commercial kit of its kind. With the advantages of the EpiFinder platform, Epigenica is helping researchers advance biomedical research, drug discovery and development, precision medicine, diagnostics, and therapeutics for aging and longevity.
mid stageBiotechnology
Board Member, Co-owner and Investor
Feb 2023
Angel investor network formed by seasoned entrepreneurs investing smart money.
Show all 7 entries ↓
Investment activity
2018–2026 · 7 investments
2018120201202332024120261
Recent (last 2 years)Earlier